Heart Pump Device Market Size, Share & Trends Analysis Report By Type, By Product (Ventricular Assist Devices, Total Artificial Hearts), By End-use (Hospital, Cardiac Centers), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global heart pump device market size was valued at USD 2.83 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 19.6% from 2023 to 2030. The growing number of individuals suffering from cardiovascular diseases (CVD), and the growing geriatric population are driving the demand for heart pump devices. However, as the pandemic progressed, there was an increased demand for heart pump products due to the higher risk of severe illness in patients with pre-existing heart conditions who contract COVID-19. This led to an increase in the adoption of these devices as a treatment option for HF patients who were also diagnosed with COVID-19.

The COVID-19 pandemic had a significant impact on the market. During the pandemic, there was a decrease in patients seeking medical attention for heart failure (HF) due to fear of exposure to the virus in hospitals and clinics. This led to a decline in the revenue of key market players during the initial phase of the pandemic.

According to the Chinese Center for Disease Control and Prevention, the case-fatality rate for COVID-19 was found to be 11% for patients with CVD, compared to the overall rate of 2.3%. As the prevalence of HF and the aging population increase, the demand for heart pumps is expected to increase over the forecast period.

The increasing prevalence of CVD and associated conditions are expected to drive market growth over the forecast period. According to an article by NCBI in May 2022, 92.1 million Americans are affected by some form of CVD, and it is predicted that 43.9% will have some type of CVD by 2030. The rising number of end-stage HF patients, coupled with the shortage of donor organs, has fueled a surge in demand for heart pump devices. The growing incidence of HF is driving market growth.

The rising investment in R&D for heart pump products is expected to drive market growth by promoting increased adoption and usage of these devices. For example, BiVACOR received a grant of USD 750,000 from the Australian government through the Targeted Translation Research Accelerator (TTRA) and Medical Research Future Fund (MRFF) program in October 2022. This initiative aims to enhance patient experience and improve quality of life while at home, thereby driving growth in the market.

Type Insights

Based on type, the implanted heart pump devices segment accounted for the largest share of 75.59% of the market in 2022. Implanted heart pump devices, also known as VADs, are becoming popular for patients suffering from HF who are not eligible for a heart transplant. These products are surgically implanted into the chest and designed to take over the heart's pumping function by continuously pumping blood from the ventricles to the rest of the body. Furthermore, advancements in technology and innovation in implantable heart pump products are expected to drive this segment's growth further. Manufacturers are developing smaller, more efficient products that require less invasive procedures, which are expected to increase the adoption of VADs as a treatment option for HF patients.

The extracorporeal heart pump devices segment is also expected to grow significantly over the forecast period. Extracorporeal heart pump products are external devices that temporarily support the heart by pumping blood outside the body and returning it to the circulatory system. They effectively treat acute HF and are used as a bridge to transplantation. The rising prevalence of heart disease and the shortage of donor hearts have driven the demand for extracorporeal products.

Product Insights

Based on product type, the ventricular assist devices (VADs) segment accounted for the largest share of the heart pump devices market in 2022. It is estimated to register the fastest CAGR of 19.8% during the forecast period. VADs are mechanical devices that assist with pumping blood from the heart's ventricles to the rest of the body. They are typically used as a temporary solution while awaiting a heart transplant but are also increasingly being used as a long-term treatment option for HF patients who are not candidates for transplantation.

Furthermore, market players' introduction of new and advanced VADs is another factor driving the segment's growth. These products are designed to be more effective, user-friendly, and affordable, which is expected to increase the demand for VADs even further. For instance, in August 2022, Abbott Laboratories disclosed data revealing that patients with advanced heart failure who received its HeartMate 3 LVAD had higher survival rates after five years than those who received the older HeartMate II LVAD. The HeartMate 3 demonstrated a 58% survival rate over the five years, compared to the HeartMate II's 44% survival rate. This is mainly due to decreased deaths related to stroke, clotting, and bleeding associated with the newer device.

End-use Insights

Based on end-use, the hospital segment accounted for the largest share of 81.05% in 2022. This growth can be attributed to the increasing number of surgical procedures being performed globally due to the rising incidence of cardiovascular diseases and the availability of skilled professionals and novel heart pump products.

The cardiac center’s segment is also expected to grow significantly over the forecast period owing to the increasing preference of individuals to undergo surgical interventions in cardiac centers. Moreover, the increasing prevalence of cardiac disease is driving demand for specialized care, and cardiac centers are well-positioned to meet this demand.

Regional Insights

In 2022, North America was anticipated to be the dominant region, with a revenue share of over 47.49%. This is mainly due to the high incidences of heart disease in the region, a large aging population, and strong healthcare infrastructure. These key factors are expected to fuel regional growth. In addition, according to the CDC, the prevalence of atrial fibrillation is estimated to rise to 12.1 million by the year 2030. This highlights a rising burden of CVD in the country, which is expected to increase the demand for heart pump devices during the forecast period.

Europe is estimated to grow at the fastest rate during the forecast period. The growth is attributed to the aging population, high prevalence of cardiovascular diseases, and advanced healthcare infrastructure. In addition, favorable government policies, increased awareness of heart pump devices, and significant investment in research and development contribute to the market's expansion, leading to wider adoption of these life-saving products in the European region.

Key Companies & Market Share Insights

Key players are introducing advanced products at affordable prices to increase their market share and implementing strategic initiatives, such as acquisitions, mergers, and collaborations, to maximize their market dominance. For instance, in September 2022, Abiomed announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for two clinical research programs related to Impella heart pumps in patients with acute myocardial infarction (AMI) and cardiogenic shock. The FDA approved the RECOVER IV randomized controlled trial (RCT), which is an on-label study for AMI cardiogenic shock patients.

In December 2022, Abiomed, Inc. was acquired by Johnson & Johnson and will continue to operate as an independent entity within Johnson & Johnson's MedTech segment. Some prominent players in the global heart pump device market include:

• Abbott

• ABIOMED

• CorWave SA

• LivaNova PLC

• Berlin Heart

• SynCardia Systems, LLC

• Jarvik Heart

• BiVACOR Inc.

• Leviticus Cardio

• Evaheart, Inc.

• Teleflex Incorporated.

• Getinge AB.

• CARMAT

• Fresenius SE & Co. KGaA

Heart Pump Device Market Report Scope

Global Heart Pump Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For the purpose of this study, Grand View Research has segmented the global heart pump device market report based on type, product, end-use, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Implanted Heart Pump Devices

  • Extracorporeal Heart Pump Devices

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Ventricular Assist Devices (VADs)

    • Left Ventricular Assist Devices (LVAD)

    • Right Ventricular Assist Devices (RVAD)

    • Bi-Ventricular Assist Devices (BiVAD)

    • Percutaneous Ventricular Assist Devices (PVAD)

  • Total Artificial Hearts (TAHs)

  • Intra-Aortic Balloon Pumps (IABPs)

  • Extracorporeal Membrane Oxygenation (ECMO)

• End-Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Cardiac Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait